<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01166269</url>
  </required_header>
  <id_info>
    <org_study_id>ILIT</org_study_id>
    <nct_id>NCT01166269</nct_id>
  </id_info>
  <brief_title>Study to Asses Efficacy of Intralymphatic Immunotherapy</brief_title>
  <acronym>ILIT</acronym>
  <official_title>Intralymphatic Specific Immunotherapy - as a New Treatment Form for Grass-pollen Allergic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TRYG Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to try a new route for specific immunotherapy (SIT). The current
      treatment form for SIT is subcutaneously (SCIT), which is a long treatment with up to 50
      injections subcutaneously in the upper arm.

      The investigators believe that there is additional effect if the allergen is injected
      directly into the lymph node, since it is here, the allergen presentation is happening. The
      trial has been performed in Switzerland with significant effect of only three injections of
      grass-allergen into a lymph node (Clinicaltrials.gov; NCT00470457).

      The investigators would like to see what happens if the the dose is doubled, so the patients
      will receive 6 injections all in all, with the same amount of allergen as the earlier study
      (1000 SQ-U). Also the outcome measurements is slightly different as the patients will note
      their symptoms in a diary.

      The patients will be divided into three groups using allocation:

      1 group with 6 injections of allergen

      1 group with 3 injections of allergen and 3 injections of placebo

      1 group with 6 injections of placebo. The trial will be double blinded.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>symptom improvement</measure>
    <time_frame>2 seasons. (2 years)</time_frame>
    <description>The patients will fill out a diary during the grasspollen-season before and after treatment. Also they will fill out a form for the general status of the season passed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of reactivity of skin prick test and Specific IgE</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>Grass-Allergen x 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive 6 injections of allergen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>grass-allergen x 3 and placebo x 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>this arm will receive 3 injections of allergen, and 3 injections of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo x 6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>this arm will receive 6 injections of placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>phleum pratense (grass-allergen)</intervention_name>
    <description>6 injections of grass-allergen. Every dose will be 1000 SQ-U.</description>
    <arm_group_label>Grass-Allergen x 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>phleum pratense (grass allergen)</intervention_name>
    <description>3 injections of grass-allergen. Every dose will be 1000 SQ-U. Also 3 injections of placebo (physiological saline)</description>
    <arm_group_label>grass-allergen x 3 and placebo x 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>physiological saline</intervention_name>
    <description>6 injections of placebo (physiological saline)in a lymph node.</description>
    <arm_group_label>placebo x 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  grass pollen allergy through at least 2 seasons

          -  positive skin prick test

          -  positive Specific IgE of at least 2. (CAP)

          -  Signed informed consent

          -  for females a negative pregnancy test.

        Exclusion Criteria:

          -  out of age limits

          -  rhinoconjunctivitis all year round.

          -  uncontrolled seasonal asthma

          -  patients treated with steroids continuously or beta-blockers.

          -  pregnancy and breastfeeding

          -  HIV, Hepatitis B+c, and other immunological diseases.

          -  psychiatric disease

          -  treatment with SCIT or SLIT within the last 5 years

          -  participation in other clinical trials within the last 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Joergen Malling, Prof. Dr. Med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Copenhagen University Hospital, Gentofte, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermato-allergological dept. K</name>
      <address>
        <city>Gentofte</city>
        <state>Hellerup</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2010</study_first_submitted>
  <study_first_submitted_qc>July 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2010</study_first_posted>
  <last_update_submitted>November 7, 2012</last_update_submitted>
  <last_update_submitted_qc>November 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Professor, Dr. Med Hans-Joergen Malling</investigator_full_name>
    <investigator_title>Professor Dr. Med.</investigator_title>
  </responsible_party>
  <keyword>grass-pollen allergy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

